Sobi Drug Patent Portfolio
Sobi owns 1 orange book drug protected by 3 US patents Given below is the list of Sobi's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8980873 | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt | 25 Mar, 2030 | Active |
| US8153632 | Oxygen linked pyrimidine derivatives | 17 Jan, 2029 | Active |
| US9573964 | Oxygen linked pyrimidine derivatives | 05 May, 2028 | Active |
Latest Legal Activities on Sobi's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sobi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9573964 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9573964 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US9573964 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US9573964 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Aug, 2022 | US8980873 |
| Initial letter Re: PTE Application to regulating agency | 01 Jul, 2022 | US9573964 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 19 Jan, 2022 | US9573964 |
|
Email Notification
Critical
| 19 Jan, 2022 | US9573964 |
|
Correspondence Address Change
Critical
| 18 Jan, 2022 | US9573964 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 18 Jan, 2022 | US8980873 |
|
Email Notification
Critical
| 18 Jan, 2022 | US8980873 |
|
Correspondence Address Change
Critical
| 16 Jan, 2022 | US8980873 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 May, 2020 | US9573964 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Sep, 2018 | US8980873 |
|
Recordation of Patent Grant Mailed
Critical
| 21 Feb, 2017 | US9573964 |
Sobi's Family Patents
Sobi Drug List
Given below is the complete list of Sobi's drugs and the patents protecting them.
1. Vonjo
Vonjo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8980873 | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
25 Mar, 2030
(4 years from now)
| Active |
| US8153632 | Oxygen linked pyrimidine derivatives |
17 Jan, 2029
(3 years from now)
| Active |
| US9573964 | Oxygen linked pyrimidine derivatives |
05 May, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vonjo's drug page